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De novo design of RNA-binding 
proteins with a prion-like domain 
related to ALS/FTD proteinopathies
Kana Mitsuhashi, Daisuke Ito, Kyoko Mashima, Munenori Oyama, Shinichi Takahashi & 
Norihiro Suzuki
Aberrant RNA-binding proteins form the core of the neurodegeneration cascade in spectrums of 
disease, such as amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD). Six ALS-related 
molecules, TDP-43, FUS, TAF15, EWSR1, heterogeneous nuclear (hn)RNPA1 and hnRNPA2 are RNA-
binding proteins containing candidate mutations identified in ALS patients and those share several 
common features, including harboring an aggregation-prone prion-like domain (PrLD) containing a 
glycine/serine-tyrosine-glycine/serine (G/S-Y-G/S)-motif-enriched low-complexity sequence and rich 
in glutamine and/or asparagine. Additinally, these six molecules are components of RNA granules 
involved in RNA quality control and become mislocated from the nucleus to form cytoplasmic inclusion 
bodies (IBs) in the ALS/FTD-affected brain. To reveal the essential mechanisms involved in ALS/FTD-
related cytotoxicity associated with RNA-binding proteins containing PrLDs, we designed artificial 
RNA-binding proteins harboring G/S-Y-G/S-motif repeats with and without enriched glutamine 
residues and nuclear-import/export-signal sequences and examined their cytotoxicity in vitro. These 
proteins recapitulated features of ALS-linked molecules, including insoluble aggregation, formation of 
cytoplasmic IBs and components of RNA granules, and cytotoxicity instigation. These findings indicated 
that these artificial RNA-binding proteins mimicked features of ALS-linked molecules and allowed the 
study of mechanisms associated with gain of toxic functions related to ALS/FTD pathogenesis.
Growing evidence indicates that disturbed RNA quality control systems mediated by aberrant RNA-binding 
proteins, such as TDP-43 and FUS, form the core of the neurodegeneration cascade in ALS/FTD1. Six 
ALS-related molecules, TDP-43, FUS, TAF15, EWSR1, heterogeneous nuclear (hn) RNPA1 and hnRNPA2 are 
RNA-binding proteins containing candidate mutations identified in ALS patients. These molecules share sev-
eral common features. First, they harbor a prion-like domain (PrLD) and are aggregation-prone2, and PrLDs 
involving self-propagating amyloid-fibril conformations exhibit two critical features: they contain a glycine/
serine-tyrosine-glycine/serine (G/S-Y-G/S)-motif-enriched low-complexity sequence (regions of protein 
sequences with biased amino acid composition)3 and are rich in glutamine and/or asparagine (Q/N)2,4. PrLDs can 
mediate pathologically aggregated states observed in the ALS/FTD brain as a result of aging, and/or ALS-linked 
mutations clustered in the PrLDs of TDP-43 and FUS and which accelerate this toxic conversion to initiate 
neurodegeneration.
Second, they are included as components of RNA or messenger ribonucleoprotein granules, such as stress 
granules (SGs), which are involved in the RNA quality control system by stabilizing and storing mRNAs and 
arresting translation to prevent the accumulation of misfolded proteins5–7. A low-complexity sequence in PrLDs 
mediates interactions between biophysical molecules and RNA granules and it drives the assembly of cytoplasmic 
RNA granules, with ALS-linked mutations in TDP-43, FUS, and hnRNPA28–11.
Third, a common pathological feature of ALS/FTD is the mislocalization of candidate RNA-binding pro-
teins from the nucleus to the cytoplasm and their subsequent formation of cytoplasmic inclusion bodies (IBs) in 
disease-affected regions. In FUS, ALS-associated mutations are clustered at the non-classical nuclear-localization 
signal (NLS) in the C-terminus, which directly impedes nuclear localization10,12–14. The mutation of a trun-
cated protein lacking a NLS (R495X) was identified as being causative of juvenile ALS with rapid disease pro-
gression, indicating that impairment of FUS nucleocytoplasmic trafficking is directly linked to motor-neuron 
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degeneration15. Given these commonalities, cytoplasmic aggregation of RNA-binding proteins could constitute 
a critical process in the development of the ALS/FTD pathological cascade linked to the RNA quality control 
system.
An emerging question involving these ALS/FTD-related RNA-binding proteins is whether their associ-
ated cytotoxicity is dependent upon specific physiological functions related to target RNAs or their robust and 
non-specific assembly with ribonucleoproteins. To address this, we generated artificial RNA-binding proteins 
harboring repeats of the G/S-Y-G/S-motif-enriched low-complexity sequence with and without enriched glu-
tamine residues and signal sequences for nuclear import/export. To minimize superfluous functions in mam-
malian cells, a well-characterized plant-based RNA-recognition domain [poly(A)-binding protein (PABPs)]16 
was selected as a standard RNA-recognition motif (RRM). These proteins exhibited features similar to those of 
ALS-linked molecules, including insoluble aggregation, formation of cytoplasmic IBs and RNA-granule compo-
nents, and instigation of cytotoxicity. These findings indicated that cytoplasmic RNA-binding proteins containing 
PrLDs can initiate neurotoxicity independent of their specific physiological functions. We propose that these arti-
ficial RNA-binding proteins effectively replicated features of ALS-linked molecules and constitute novel experi-
mental molecules that enable enhanced understanding of the molecular basis of ALS/FTD-related cytotoxicity.
Results
Characterization of SYG and SYGQ-nuclear-export signal (NES)-green fluorescent protein 
(GFP) expression in cultured cells. To reveal cytotoxicity induced by RNA-binding proteins containing 
PrLDs, we generated synthetic cDNAs encoding 67 repeats of the G/S-Y-G/S motif, 50 repeats of G/S-Y-G/S + Q 
or G/S-Y-G/S + Q/N motifs containing the PABP RRM, signal sequences for nuclear import/export, and GFP tags 
(Fig. 1a and Supplementary information). We assembled the base pairs necessary to encode the G/S-Y-G/S motif 
and minimize repeats of the nucleotide sequence to avoid formation of aberrant RNA structures. Additionally, 
we used the well-characterized PABP RRM from Citrus sinensis, which shares 43% identity with the human 
PABPN116, to minimize the possibility of functional redundancy in mammalian cells. Furthermore, we added a 
NLS (MPKKKRKVGG) or NES (MLPPLERLTLDGG) to investigate compartment-specific cytotoxicity.
We inserted these cDNAs into a mammalian expression vector, followed by transfection into various cell 
lines and analysis by western blot. As shown in Fig. 1b, we detected full-length forms of the SYGQ-NES [pre-
dicted size: ~68 kDa; estimated isoelectric point (pI): 5.76; http://web.expasy.org/compute_pi/] and SYG-NES 
proteins (predicted size: ~68 kDa; estimated pI: 5.76) at ~73 kDa according to western blot results. Both artificial 
proteins were also detected within the stacking gel, indicating that both were prone to aggregation and forma-
tion of high-molecular-weight complexes. A series of deletion experiments revealed that the SYG ± Q PrLD was 
essential for the formation of these high-molecular-weight complexes (Fig. 1c). However, we observed low levels 
of the SYGQ/N-NES protein (predicted size: ~68 kDa; estimated pI: 5.76) in 293 T cells, with nearly undetectable 
formation of high-molecular-weight complexes (Fig. 1d).
Furthermore, soluble and insoluble fractionation showed that the SYG and SYGQ-NES proteins were present 
in the RIPA-insoluble and urea-soluble fractions, indicating that both formed strongly insoluble aggregates simi-
lar to candidate proteins found in the brains of ALS/FTD patients (Fig. 1e). Therefore, we focused on the SYG and 
SYGQ-NES proteins in subsequent experiments.
Characterization of IBs formed in SYGQ-NES-expressing cells. A characteristic feature of ALS/FTD 
is the presence of IBs consisting of ALS-related RNA-binding proteins and immunoreactive to p62/sequestosome 
1 throughout the affected regions. To examine subcellular localization of the artificial proteins, we performed 
immunocytochemistry in 293 T cells (Fig. 2a). Our results indicated that the SYGQ-NES protein formed char-
acteristic p62-positive cytosolic IBs [mean percentage of cells with IBs ± standard deviation: 7.28 ± 0.28 (n = 3); 
Fig. 2b and c], but that this activity was rarely observed for the SYG-NES protein. Similar SYGQ-NES IBs were 
observed in other cell lines, including Neuro2a [percentage of cells with IBs: 10.1% (7 cells with IBs/69 cells 
expressing SYGQ-NES; n = 1)] and HeLa cells [percentage of cells with IBs: 3.8% (3 cells with IBs/79 cells express-
ing SYGQ-NES; n = 1)] (Supplementary Fig. 1).
IBs formed by molecules resulting from deletion experiments were rarely observed (Fig. 2 and Supplementary 
Fig. 2). Additionally, we also generated other artificial Q/N-rich prion-like proteins, synthetic prion-forming 
domains (sPFD) designed by a prion-aggregation-prediction algorithm and control prion-forming domains 
(cPFD), which exhibit low prion propensity and used sPFD as a control (Supplementary information)17. 
Unexpectedly, western blot showed that cPFD, and not sPFD, formed high-molecular-weight complexes in the 
stacking-gel for unknown reasons (Supplementary Fig. 2). All mutant constructs, including those encoding the 
sPFD protein, showed rare IB formation (Fig. 2), indicating that the SYGQ-repeat PrLD, RRM, and cytoplasmic 
localization domains were critical for IB formation.
Previous studies demonstrated that IBs involving TDP-43 and FUS in ALS/FTD-patient brain tissue recruit 
other RNA-binding proteins, such as components of SGs8,10,13,18–20. As shown in Fig. 3a, SYGQ-NES IBs exhibited 
co-localization with endogenous TDP-43 [percentage of TDP-43+ IBs: 58.5% (24 TDP-43+ IBs/41 IBs; n = 1)], 
SG markers {[Ras GTPase-activating protein-binding protein 1 (G3BP); percentage of G3BP+ IBs: 32.4% (12 
G3BP+ IBs/37 IBs; n = 1)], HuR [percentage of HuR+ IBs: 12.5% (5 HuR+ IBs/40 IBs; n = 1)], Ataxin2 [percent-
age of Ataxin2+ IBs: 74.4% (29 Ataxin2+ IBs/39 IBs; n = 1)], and SMN [percentage of SMN+ IBs: 15.4% (6 SMN+ 
IBs/39 IBs; n = 1)]}, mRNA transporters, fragile X mental retardation protein (FMRP) [percentage of FMRP+ IBs: 
52.5% (21 FMRP+ IBs/40 IBs; n = 1)], and Staufen [percentage of Staufen+ IBs: 26.8% (11 Staufen+ IBs/41 IBs; 
n = 1)]. Notably, SYGQ-NES IBs recruit components of SGs, including nuclear proteins such as TDP-43 and HuR; 
however, they show varying staining patterns, indicating that SYGQ-NES IBs possess partial features of SGs, and 
possibly belong to diverse subcellular entities known as heterogeneous RNA granules6.
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Furthermore, administration of the inhibitor of translational elongation, emetine, stabilizes polysomes and 
suppresses SG formation21. As shown in Fig. 3b, treatment with this drug dispersed IBs [(mean percentage of 
cells containing IBs formed under normal conditions in the presence and absence of emetine: 11.1 ± 0.6% vs. 
5.3 ± 1.7%, respectively (P < 0.05)] in 293 T cells expressing SYGQ-NES and also mutant FUS10, but not aggre-
somes containing mutant forms of superoxide dismutase 1. These findings strongly suggested that SYGQ-NES IBs 
exhibited characteristics associated with SGs.
Figure 1. Expression in cultured mammalian cells of artificial RNA-binding proteins containing PrLDs. 
(a) Schematic diagram showing artificial RNA-binding proteins containing PrLDs, as well as the deletion 
constructs. All constructs contained a GFP tag at the C-terminus. sPFD: synthetic prion-forming domain; 
cPFD: control prion-forming domain [exhibiting low degrees of prion propensity17]. (b) Immunoblot analysis 
of SYG/SYGQ-NES expression in transfected HeLa and Neuro2a cells. Lysates of cells transiently transfected 
with plasmids were fractionated by SDS-PAGE and analyzed by immunoblot using a mouse monoclonal anti-
GFP antibody. α-tubulin was used as an internal control. Asterisks (*) indicate aggregation resolved using 
stacking gels. Arrowheads indicate full-length SYG/SYGQ-NES. Green arrows indicate predicted size. (c) 
Immunoblot analysis of deletion constructs expressed in 293 T cells. Protein (12 μg/lane) was loaded on a 4% 
to 20% Tris-glycine gradient gel and detected using an anti-GFP antibody for western blot analysis. Asterisks 
(*) indicate aggregation resolved using stacking gels. (d) Immunoblot analysis of SYG, SYGQ, and SYGQ/N-
NES expression in transfected 293 T cells. α-tubulin was used as an internal control. Asterisks (*) indicate 
aggregation, and arrowheads indicate full-length proteins. (e) Neuro2a cell lysates expressed of SYG/SYGQ-NES 
were separated into RIPA-soluble and -insoluble urea fractions. Full-length proteins (indicated by arrowheads) 
were detected in only the insoluble fractions.
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Furthermore, ALS-causative mutations in FUS abnormally interact with SMN and lead to loss of nuclear 
Gemini of coiled bodies (GEM), and mutation of TDP-43 or FUS disrupt GEM assembly or stabilization22–26. 
Here, we observed that expression of SYG/SYGQ-NES proteins significantly reduced nuclear GEMs consistent 
with results observed in the presence of other ALS-linked RNA-binding protein (Fig. 4).
Figure 2. SYGQ-NES proteins form IBs in cultured cells. (a) At 48-h post-transfection, 293 T cells were 
counterstained with 4′,6-diamidino-2-phenylindole (DAPI) (blue). (b) Percentage of cells harboring IBs in ~300 
transfected cells from three independent experiments (mean ± standard deviation). Plots indicate mean values 
from each experiment (n = 3). Scale bar: 10 μm. Asterisks (*) indicate significant differences between SYGQ-
NES-GFP vs. GFP (control). *P < 0.0001, vs. GFP (One-way ANOVA). (c) Cytoplasmic IBs of SYGQ-NES are 
p62-positive. Scale bars: 10 μm.
www.nature.com/scientificreports/
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SYG/SYGQ-NES proteins are recruited to SGs. SGs are formed as cytoplasmic foci that aggregate 
mRNA and RNA-binding proteins under stress conditions, such as hypoxia and heat shock. SGs function as part 
of the RNA quality control system by stabilizing and storing mRNAs and arresting translation to prevent the 
Figure 3. Interactions between SYGQ-NES and other ALS-related RNA-binding proteins in IBs. (a) 293 T 
cells expressing SYGQ-NES (green) were labeled with antibodies against TDP-43, G3BP, HuR, Ataxin2, SMN, 
FMRP and Staufen (red). Note that endogenous TDP-43 is predominantly nuclear but partially cytoplasmic 
in 293 T cells expressing naïve GFP (green) as control. Scale bar: 10 μm. (b) Emetine disassembles SYGQ-NES 
IBs. Treatment with 10 μg/mL emetine for 1 h resulted in disassembly of cytoplasmic IB formation in 293 T cells 
expressing SYGQ-NES-GFP and mutant FUS-GFP, but not those expressing mutant SOD1-GFP. Plots indicate 
mean values from each experiment (n = 3). Scale bar: 10 μm. *P < 0.05, vs. no treatment (Student’s t test). Plots 
indicate mean values of each experiment.
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accumulation of misfolded proteins27. ALS-linked RNA-binding proteins TDP-43, FUS, and Ataxin2 are SG com-
ponents, and their mutation leads to the formation of aberrant SGs in vitro and in vivo8–11,18. To examine whether 
SYGQ-NES proteins are recruited to SGs, we performed double immunofluorescence staining in HeLa cells, 
which is commonly used for examining the characters of SG6–8 after treatment with arsenite, a well-established 
SG inducer (38). As shown in Fig. 5, both artificial proteins, predominantly SYGQ-NES, were recruited to SGs 
following arsenite treatment. A series of deletion experiments revealed that SYG/SYGQ repeats, cytoplasmic 
localization domains, and partial Q-rich domains and RRMs were critical for SG localization. Furthermore, anal-
ysis of the number of HeLa cells expressing SYG/SYGQ-NES proteins with arsenite-induced SGs showed that 
Figure 4. GEM number following expression of artificial RNA-binding proteins containing PrLDs. HeLa cells, 
in which GEM is well-observed, transiently expressed SYG or SYGQ-NES (green). Numbers of GEM formation 
was assessed by immunostaining with anti-SMN (red). Graphs show the average number of GEMs formed in 
cells expressing SYG or SYGQ-NES (n = 3). *P < 0.002, vs. GFP (One-way ANOVA). Scale bar: 10 μm
www.nature.com/scientificreports/
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SYGQ-NES expression increased SG formation in a manner similar to that observed with the ALS mutants TDP-
43 (Q343R) and FUS (P525L) (Fig. 6). These findings indicated that SYGQ-NES expression dysregulated SG 
formation similar to results observed in the presence of ALS-associated mutants8–11.
SYG/SYGQ-NES cytotoxicity. To determine whether SYG/SYGQ-NES expression leads to neurotoxicity, 
we measured neurite length on differentiated Neuro2a cells, a well-established model of neurite outgrowth28–30. 
SYG/SYGQ-NES-expressing cells become rounded and shrink, and showed shorter neurites compared with those 
observed on control cells (Fig. 7). We also observed shorter neurites in cells containing ALS-related TDP-43 
(Q343R) and wild type FUS constructs. Additionally, deletion experiments revealed that SYG/SYGQ repeats, 
cytoplasmic localization domains and RRMs were critical for the disturbance of neurite outgrowth (Fig. 8a). 
Figure 5. SYG/SYGQ-NES is recruited to SGs in arsenite-treated HeLa cells. Following 1 h treatment with 
0.5 μM arsenite, HeLa cells were fixed and immunostained for SG markers and with the anti-HuR antibody. 
Graphs indicate the ratio of the mean intensity of GFP in SGs to that observed in the cytoplasm. The fluorescent 
distributions in SGs from cells expressing SYG/SYGQ-NES and ΔRRM were higher than those observed in cells 
expressing GFP alone. *P < 0.003, vs. GFP; #P < 0.0002; vs. SYGQ-NES (one-way ANOVA). Scale bar: 10 μm.
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We then assessed the induction of cell death following transfection of the artificial molecules as determined by 
propidium iodide-positive (PI+) cells in GFP-positive Neuro2a cells and cell sorting. As shown in Fig. 8b, we 
observed increased levels of PI + cells expressing both artificial proteins, but higher levels in the presence of 
SYG-NES, indicating that expression of either SYG or SYGQ-NES resulted in cytotoxicity.
Figure 6. SG formation involving artificial RNA-binding proteins containing PrLDs. HeLa cells expressing 
GFP, SYG/SYGQ-NES, TDP-43-GFP, or FUS-GFP were double labeled with monoclonal anti-GFP and -HuR 
antibodies following a 1 h treatment with arsenite (0.5 mM). Approximately 25 transfected cells from three 
independent experiments were used to quantify the number of SGs formed per cell. *Indicates statistically 
significant differences (*P < 0.04 vs. GFP, One-way ANOVA). Scale bar: 10 μm.
www.nature.com/scientificreports/
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Discussion
Increasing evidence supports hypotheses involving gain of toxic functions resulting from cytoplasmic accu-
mulation of RNA-binding proteins involved in ALS/FTD pathogenesis. Overexpression of human TDP-43 
and FUS in mice causes progressive motor-neuron degeneration similar to ALS phenotypes, including cyto-
plasmic aggregation31–35. However, several FUS-knockout mutant models do not exhibit phenotypes associ-
ated with motor-neuron dysfunction36,37, although expression of mutant FUS can also directly recapitulate 
ALS-like motor-neuron abnormalities in mice independent of reductions in FUS activity38,39. Haploinsufficiency 
mutations involving FUS and that lead to nonsense-mutation-mediated mRNA decay were identified in an 
essential-tremor-affected family that did not reveal any signs of ALS40. Therefore, these findings suggested that 
mislocated RNA-binding proteins are critical for neurodegeneration development in a gain of toxic function 
manner.
Figure 7. Neurites in differentiated Neuro2a cells expressing SYG/SYGQ-NES. Representative images of 
immunocytochemistry for SYG/SYGQ-NES-positive differentaited Neuro2a cells using the anti-βIII-tubulin 
antibody. Graphs indicate quantitative data from neurite-bearing cells. Neuro2A cells containing neurites 
exhibiting diameters of at least two cell-bodies in length were scored as neurite-bearing cells (n = 3 independent 
experiments; mean ± standard deviation). *P < 0.05, one-way ANOVA. Scale bar: 20 μm.
www.nature.com/scientificreports/
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Figure 8. Cytotoxicity induced by SYG/SYGQ-NES. (a) Neurites in differentiated Neuro2a cells expressing 
deletion variants of SYG and SYGQ-NES. Representative images of βIII-tubulin immunostaining of 
differentiated Neuro2a cells. sPFD-NES and cPFD-NES were used as a negative control. Graphs indicate 
quantitative data of βIII-tubulin-positive neurite-bearing neurons (n = 3 independent experiments; 
mean ± standard deviation) *P < 0.03 (One-way ANOVA). Scale bar: 20 μm. (b) Dead cells to the GFP positive 
cells by fluorescence-cell sorting. Neuro2a cells were subjected to transfection with SYG, SYGQ-NES, or mutant 
FUS tagged with GFP, followed by PI staining after a 48 h incubation for the detection of dead (GFP+PI+) 
cells. cPFD-NES, which shows similar GFP intensity as SYG and SYGQ-NES, was used as a negative control. 
Representative fluorescence-activated cell sorting pictograms. The percentage of dead (GFP+PI+) cells 
are shown, and the graph indicates the mean ± standard deviation (n = 5). Asterisks *indicate a significant 
differences (*P < 0.05; Student’s t test).
www.nature.com/scientificreports/
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Our findings provided several insights into the cellular-biochemical features of ALS/FTD-linked RNA-binding 
proteins. Artificial RNA-binding proteins containing SYG/SYGQ repeats initiated aggregation and assembly with 
SG components and caused neuronal toxicity. Low-complexity sequences referred to as G/S-Y-G/S motifs, cyto-
plasmic localization and RRMs are essential for inhibition of neurite outgrowth (Fig. 8). SG localization requires 
G/S-Y-G/S motifs, cytoplasmic localization domains, partial Q-rich domains, and RRMs (Fig. 5), and IB forma-
tion also requires Q-enriched G/S-Y-G/S motifs, cytoplasmic localization domains, and RRMs (Fig. 2). Notably, 
the SYG-NES protein showed formation of high-molecular-weight complexes according to western blot analysis 
(Fig. 1), but we rarely observed IB formation in cells expressing SYG-NES proteins (Fig. 2). Although it might 
be possible that cells expressing SYG-NES proteins were unhealthy (rounded, shrunken, and floating) prior to 
the maturation of visible IBs, IB formation might be required for additional cellular process(es) beyond charac-
teristics required formation of high-molecular-weight complexes. These characteristics were distinct from those 
observed in a protein harboring a de novo design of sPFDs17 (Figs 2,5, and 8) and other ALS-linked aggregated 
proteins, such as SOD-1 (Fig. 3b), indicating that the artificial SYG/SYGQ-NES proteins lacking specific physio-
logical functions associated with target RNAs effectively mimicked specific pathological features associated with 
ALS/FTD-linked RNA-binding proteins.
Although the detail pathological mechanism of the SYG/SYGQ-NES protein remains unknown and requires 
further study, recent evidence suggests that ALS-linked RNA-binding proteins, such as TDP-43 and FUS, are 
mislocated to the cytoplasm and might affect target RNAs and other RNA-binding proteins, resulting in impair-
ment of RNA metabolism and RNA quality control mechanisms, such as those associated with SGs, during neu-
rodegeneration1,41. The SYG-NES protein is strongly cytotoxic in the absence of IBs, indicating that IB formation 
is unnecessary for cytotoxicity (Figs 2 and 8); however, high-molecular-weight complexes of low-complexity 
sequences, including G/S-Y-G/S motifs, might interfere with other RNA-binding proteins, including TDP-43 and 
other SG components, resulting in cell toxicity as a result of RNA dysregulation.
Several points should be kept in mind during the exploration of ALS/FTD pathogenesis using artificial SYG/
SYGQ-NES proteins, and alternative interpretations should be considered. First, although most ALS/FTD-linked 
RNA-binding proteins are ubiquitously expressed in all tissues, ALS/FTD is a degenerative disease that predom-
inantly affects the frontal lobe containing primary and secondary motor neurons from the spinal cord, which are 
anatomically related. Therefore, future studies need to confirm motor-dominant neurodegeneration following 
SYG/SYGQ-NES expression under the control of a ubiquitous promoter in transgenic animals.
Second, abundant molecular and cellular evidence suggests that the misfolding of specific proteins, such as 
α-synuclein, β-amyloid, and tau, can act as seeds for aggregation and can be transmitted intercellularly, thereby 
constituting a manner of self-dissemination similar to that observed with prions42. Recent neuropathological 
studies of postmortem brains from ALS patients described a pattern of phospho-TDP-43 immunoreactivity that 
agrees with a systematic spreading of TDP-43-related pathology43,44. Cell-biological studies also showed TDP-43 
soma-to-soma transmission between cells and propagation within neuroanatomical systems across axon termi-
nals45. Therefore, future studies should examine whether artificial proteins harboring low-complexity sequence(s) 
in PrLD(s) also exhibit similar mechanisms of seeded aggregation and propagation.
Third, affected regions in most ALS patients are characterized by TDP-43-positive IBs in the cytoplasm 
and also by the depletion of TDP-43 protein in the nucleus46,47. Analyses by cross-linking and immunopre-
cipitation suggested that there might be thousands of RNA molecules targeting TDP-43 and FUS during the 
mRNA-maturation and gene-regulation processes48–50. A study using a conditional mouse TDP-43 gene-targeting 
approach in spinal cord motor neurons reported progressive development of ALS-related phenotypes51. Therefore, 
theories supporting a loss-of-function phenotype associated with TDP-43 proteinopathy and leading directly to 
RNA dysregulation and development of neurodegeneration remain plausible46,47,52. In this study, we were unable 
to directly examine loss-of-function phenotypes associated with ALS pathogenesis using artificial proteins.
Forth, analysis by cross-linking and immunoprecipitation of sequences suggested that approximately 
30% mRNA of the murine transcriptome interacted with TDP-43 and FUS48–50. Therefore, FUS and TDP 
43-proteinopathies possibly cause gross RNA dysregulation rather than specific mRNA disruptions in ALS/FTD 
development. Therefore, an RRM of PABP from Citrus sinensis, which represents an authentic ortholog of the 
animal PABPs, was used for these artificial proteins to avoid specific binding to RNA in mammalian cells. We 
speculated that the overexpressed plant-based RRM interacted widely and non-specifically with mRNAs and 
caused gross RNA dysregulation; however, this does not exclude the possibility that off-target tight-binding to 
unexpected RNAs might affect the interpretations in studies using de novo proteins. Future studies should define 
comprehensive artificial SYG/SYGQ-NES proteins -RNA interaction and compare it with other ALS-linked RNA 
binding protein interactions.
Finally, most neurodegeneration-associated aggregated proteins, such as tau and TDP-43, are easily targeted 
by protein degradation systems and are multiply fragmented in the affected brain47,53,54. As shown in Fig. 1, many 
low molecular weight degradation products of SYG/SYGQ-NES were also detected using immunoblot analysis. 
Despite the presence of a prominent ~27 kDa fragment, which is predicted to be naïve GFP from the molecular 
weight, we cannot exclude the possibility of degradation products having unexpected effects and resulting in 
modified phenotypes. Here, the instability index for SYGQ-NES calculated by ProtParam (http://web.expasy.
org/protparam/) was high (49.22), indicating that this must be improved to ensure stable expression in future 
studies. However, our findings suggested that the use of de novo proteins, specifically SYG/SYGQ-NES, effectively 
allowed the study of mechanisms associated with gain of toxic functions related to ALS/FTD pathogenesis. These 
results support the acquisition of an enhanced understanding of RNA dysregulation mediated by aggregated 
cytoplasmic RNA-binding proteins and promote the development of new strategies for the treatment of ALS/
FTD proteinopathies.
www.nature.com/scientificreports/
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Materials and Methods
cDNA and plasmids. cDNAs encoding SYG/SYGQ-NES/NLS and synthetic prion-forming domain (sPFD)/
control prion-forming domain (cPFD)-NES/NLS (Sequences are shown in Supplementary information) were 
synthesized (GenScript, NJ, USA) and subcloned into pcDNA (3.1) or pEGFP-N1 (Clontech, CA, USA) or. Wild 
type and mutant TDP-43 and FUS were described in previous papers8,10.
Cell culture. HeLa human carcinoma cells, human embryonic kidney 293 cells (293 T cells), were maintained 
in Dulbecco’s modified Eagle’s medium (Gibco, Grand Island, NY) containing 10% fetal bovine serum. Neuro2a 
neuroblastoma cells were cultured in αMEM (Gibco) supplemented with 10% fetal bovine serum. Transfections 
were performed using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s instructions. 
Neuro2a cells were differentiated where stated by incubating in DMEM supplemented with 2% (vol/vol) FBS and 
20 μM retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) for 24 h.
Antibodies and reagents. Mouse monoclonal anti-ubiquitin, HuR, and GFP were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal anti-α tubulin was from Invitrogen. Mouse 
monoclonal Anti-βIII Tubulin (2G10), p62/SQSTM1, MAP2 and FMRP was obtained from Millipore (Billerica, 
MA). Rabbit polyclonal anti-N-terminus FUS was from Bethyl Labs (Montgomery, TX, USA). Anti-TDP-43 
and G3BP antibodies were from Proteintech (Chicago, IL, USA). Rabbit polyclonal anti-GFP antibody was from 
Rockland Immunochemicals Inc. (Gilbertsville, PA, USA). Mouse monoclonal anti-GFP antibody was from Santa 
Cruz Biotechnology, Inc (Dallas, TX, USA).Mouse Anti-Ataxin-2 was purchased from BD Biosciences (Sparks, 
MD, USA). Rabbit polyclonal anti-GAPDH antibodies were from Cell Signaling Technology (Beverly, MA, USA). 
Propidium iodide was purchased from Dojindo (Kumamoto, Japan). Emetine, and Arsenite was purchased from 
Sigma-Aldrich.
Immunoblot analysis. Cells were briefly sonicated in cold lysis buffer [50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.5% NP-40, 0.5% sodium deoxycholate, 0.25% sodium dodecyl sulfate, 5 mM EDTA, and protease inhibi-
tor cocktail (Sigma-Aldrich)]. Cell lysates were separated using SDS-PAGE with 10% Tris-glycine gel, after which 
proteins were transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). The membrane 
was incubated with primary antibodies, followed by horseradish peroxidase-conjugated secondary antibodies 
and then visualized using enhanced chemiluminescence reagents (PerkinElmer Life Sciences, Boston, MA, USA). 
Protein levels were determined by densitometry using an Epson ES-2000 scanner and Image J (National Institutes 
of Health, Bethesda, MD, USA).
To examine the solubility profile of artificial protein, sequential extractions were performed. The cells were 
lysed in cold RIPA buffer (50 mM Tris, 150 mM NaCl, 1% NP-40,5 mM EDTA, 0.5% sodium deoxycholate, and 
0.1% SDS, pH 8.0 + Protease inhibitors). The cell lysates were cleared by centrifugation at 100,000 × g for 30 min 
at 4 °C to generate the RIPA soluble samples. To prevent carry-overs, the resulting pellets were washed with RIPA 
buffer twice. RIPA insoluble pellets were then extracted with urea buffer (7 M urea, 2 M thiourea, 4% CHAPS, 
30 mM Tris, pH 8.5 + Protease inhibitors), and centrifuged at 100,000 × g for 30 min at 22 °C.
Immunofluorescence with cultured cells. At 48 h after transfection, cells were fixed with 4% para-
formaldehyde on ice for 10 min and then permeabilized in 0.2% Triton X-100 at room temperature for 10 min. 
Post-fixation with 4% paraformaldehyde on ice for 5 min followed. After blocking of nonspecific binding, cover-
slips were incubated with primary antibodies and then incubated with Alexa 488 and/or Alexa 586-conjugated 
secondary antibodies (Invitrogen). Immunofluorescent staining was examined using a Leica TCS SP5 confocal 
microscope (Leica, Wetzlar, Germany).
Well-defined cytoplasmic foci of 1.0–2.5 μm diameter were counted as IBs. To detect cell death, cell were 
trypsinized and stained with 1 μg/ml propidium iodide (Dojindo, Japan). Cell sorting was performed using 
MoFlo XDP (Beckman Coulter, IN, USA).
For cytotoxicity analysis in differentiated Neuro2a cells, neurites in more than 30 transfected cells from 
independent experiments (n = 3) were evaluated using ImageJ, and cells containing neurites of at least two 
cell-body-diameter length were scored as neurite-bearing cells28,29.
Statistical analysis. Statistical analysis of the data was performed by one-way ANOVA with Fisher’s pro-
tected least squares difference test or Student’s t-test using the Statview 5.0 system (Statview, Berkley, CA, USA).
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